<DOC>
	<DOCNO>NCT02303002</DOCNO>
	<brief_summary>This safety efficacy study botulinum toxin type A subject glabellar frown line .</brief_summary>
	<brief_title>Efficacy Safety Botulinum Toxin Type A Injection Treat Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate severe glabellar frown line Female male , 30 65 year age good general health Women childbearing potential must agree use effective method birth control course study Willing refrain receipt facial filler , laser treatment use product affect skin remodel cause active dermal response Any neurological condition may place subject increase risk exposure Botulinum Toxin Type A amyotrophic lateral sclerosis motor neuropathy , LambertEaton syndrome , myasthenia gravis Muscle weakness paralysis , particularly treatment area Active skin disease infection irritation treatment area Facial asymmetry , deep dermal scarring , inability substantially lessen glabellar frown line manually spread apart Treatment Botulinum Toxin Type A face last 6 month last 3 month anywhere body</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>